CHF 5259

DRUG2 trials

Sponsors

Chiesi Farmaceutici S.p.A.

Conditions

COPDChronic Obstructive Pulmonary Disease

Phase 2

Efficacy and Safety of Glycopyrrolate Bromide of COPD Patients

CompletedNCT02189577

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease

Start: 2014-06-30End: 2015-02-28Updated: 2021-10-29

A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease

CompletedNCT03084796

Chiesi Farmaceutici S.p.A.Chronic Obstructive Pulmonary Disease, COPD

Start: 2017-07-28End: 2018-06-06Updated: 2021-06-15